🔗 Share this article

While America proceeds with sweeping changes to its immunization recommendations, one figure has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports physician and epidemiologist who initially gained attention by questioning coronavirus vaccines during the global health crisis and has concentrated on possible deaths following Covid vaccination in her short position at the Food and Drug Administration.

Proposed Overhauls to Pediatric Vaccine Schedule

Public health authorities were set to announce sweeping changes to the childhood vaccine schedule recently, aligning the US with the Danish national calendar, sources say – a significant shift that would put the US out of alignment with much of the international standard with insufficient data for benefit. The planned update has been postponed until the coming year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to present at the meeting. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the division this year.

A New Direction at the Agency

This interim role could signify a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Prasad strengthen their influence at the agency – and it signals a greater focus upon reevaluating long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for halting specific childhood shot schedules in the US in order to be more similar to Denmark's approach, a country with universal health coverage and a citizenry approximately the population of the state of Wisconsin.

To date public appearances, she has kept her attention on immunizations – traditionally the purview of Dr. Prasad, chief of the FDA’s CBER – instead of drug regulation.

Questions Over Qualifications

The appointee has no obvious background in pharmaceutical research, oversight or administrative roles, which has been typical for former directors of the biologics center. She has been employed at the FDA as a key advisor to the FDA chief and CBER since spring.

“She appears not to have the requisite experience” for overseeing the pharmaceutical oversight division, said Jonathan Howard. “She’s never run a scientific study. She has no expertise in managing a sizeable institution. She lacks background in industry regulation.”

Previous directors of CBER would “understand regulatory frameworks and the science of pharmaceutical innovation”, noted a former acting FDA commissioner. “Frankly, she doesn’t have the sort of resume that prior appointees who ran the center have had.”

The drug center has an enormous range of responsibilities at the FDA, Woodcock pointed out.

“The public just focuses on the novel medication approvals, but the generic drug division approves a multitude of off-brand pharmaceuticals. There’s a biosimilars program, non-prescription drug unit and other areas, and all of those need to be managed,” Dr. Woodcock noted. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative aspect to the role, which supervises in excess of 5,000 staff members. “It is a huge leadership role, if you perform it correctly,” Woodcock said.

Response and Contentious Policies

When asked about concerns about Dr. Høeg's credentials and whether this assignment signifies increased cooperation among agency officials on vaccines, a representative responded that the “inquiries are based on flawed presumptions”.

“This background aligns with the responsibilities of her position,” the spokesperson stated, citing the period Høeg spent advising the FDA commissioner on “drug safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's new priority voucher program, a disputed rapid drug-approval program that allegedly worried her former heads. “By what process are these drugs being chosen for this fast-track system? Who takes the decisions?” Howard said. “There’s a lot of lack of transparency going on at the agency right now.”

In general, he stated, “the Food and Drug Administration seems to be moving towards laxer oversight of all drugs, with the exception of vaccines.”

Public Track Record on Immunizations

Regarding immunizations, Høeg has a clearer, if problematic, history, Howard said. She released a research paper using unconfirmed crowd-sourced reports to assess the frequency of myocarditis after Covid immunization. She counseled the Florida top health official Joseph Ladapo, who allegedly have modified findings to imply Covid vaccinations are more dangerous than they are.

Part of her “policy goals” for the new administration encompassed altering regulations for recently developed shots and ending “unnecessary” vaccines, she remarked post-election on a audio program. At the FDA, Høeg has according to sources proposed excluding teenage boys from getting Covid vaccines.

“She’s an thorough ideologue who starts off with her preconceived notions and works backwards to retrofit the data in a extremely disingenuous, fraudulent fashion,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other skeptics, {like|